Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion
- 24 September 2010
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 400 (3) , 437-441
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetesCurrent Medical Research and Opinion, 2010
- Incretin-Based TherapiesDiabetes Care, 2009
- Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetesExpert Opinion on Emerging Drugs, 2008
- Incretin-Based Therapies in Type 2 Diabetes MellitusThe Journal of Clinical Endocrinology & Metabolism, 2008
- DPP4 Inhibitors: a new approach in diabetes treatmentAdvances in Therapy, 2008
- Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapiesCurrent Medical Research and Opinion, 2007
- Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: Predominant localization in pancreatic polypeptide-secreting PP-cellsBiochemical and Biophysical Research Communications, 2006
- Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptorBiochemical and Biophysical Research Communications, 2005
- Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?Diabetes, 1994
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992